Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer

Bentley, Tanya G. K.; Schroeder, Brock E.; Schnabel, Catherine A.; Erlander, Mark G.; Hsiao, Wendy; Ortendahl, Jesse; Broder, Michael S.

doi:10.3111/13696998.2014.909817

Cited by 3 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CancerTYPE ID is an objective molecular test of 92 genes that is used to help identify the site of origin and the histologic subtype of tumors when it is in question. 16 Boon et al 17 reported on the use of firstline ADT in 35 patients with metastatic ARpositive salivary cancer and demonstrated that treatment with ADT showed better response, clinical benefit, and overall survival compared with patients treated with supportive care. The median progression-free survival for patients treated with ADT in their study was 4 months, with median duration of clinical benefit of 11 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Rare Case of Prostate-Specific Antigen–Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance

Andrews

Ahmed

Motterle

et al. 2020

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

A 62-year-old man presented with a rising serum concentration of prostate-specific antigen (PSA) to 53.3 ng/mL (to convert to mg/L, multiply by 1) and a PSA doubling time of 2.6 months. Computed tomography, fluorodeoxyglucoseepositron emission tomography, and C-11 choline positron emission tomography demonstrated a parotid mass with innumerable lytic bone lesions and diffuse metastatic disease to the neck and mediastinal lymph nodes. Mediastinal lymph node biopsy revealed salivary ductal adenocarcinoma that produced PSA and demonstrated androgen receptor sensitivity. The patient had a prolonged clinical benefit to firstand second-line hormone therapy, and his PSA levels correlated with treatment response, development of hormone resistance, and progression. In summary, urologists, pathologists, and primary care providers should be aware that a rising PSA level in the setting of a head and neck mass in a patient without a history of prostate cancer does not constitute a diagnosis of metastatic prostate adenocarcinoma and that other primary tumors should be considered and a broader imaging and pathologic evaluation is indicated.

show abstract

Section: Discussionmentioning

confidence: 99%

“…CancerTYPE ID is an objective molecular test of 92 genes that is used to help identify the site of origin and the histologic subtype of tumors when it is in question. 16 …”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Prostate-Specific Antigen–Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance

Andrews

Ahmed

Motterle

et al. 2020

Mayo Clinic Proceedings: Innovations, Quality & Outcomes

View full text Add to dashboard Cite

show abstract

“…An increase in survival, improved life quality and a decrease in misdiagnoses and decreased cost were positive attributes identified from a patient's perspective. (Bentley et al, 2014).…”

Section: Declarationsmentioning

confidence: 99%

Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary

Chauhan

Farooqui

Silva

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: Neuroendocrine tumors (NETs) are rare tumors that can originate from any part of the body. Often, imaging or exploratory surgery can assist in the identification of the tumor primary site, which is critical to the management of the disease. Neuroendocrine tumors (NETs) of unknown primary constitute approximately 10-15% of all NETs. Determining the original site of the tumor is critical to providing appropriate and effective treatment. Methods: We performed a retrospective review of neuroendocrine tumors at our institution between 2012 and 2016 using a 92-gene cancer ID analysis. Results: 56 patients with NETs of unknown primary were identified. Samples for 38 of the 56 underwent the 92-gene cancer ID analysis. The primary site of the tumor was identified with >95% certainty in 35 of the 38 patients. Conclusion: The 92-gene cancer ID analysis identified a primary site in 92% of our NETs study cohort that previously had been unknown. The results have direct implications on management of patients with regard to FDA-approved treatment options.

show abstract

Molecular Pathology of Lung Cancer

Saller

Boyle

2021

Cold Spring Harb Perspect Med

View full text Add to dashboard Cite

Cost effectiveness of a 92-gene assay for the diagnosis of metastatic cancer

Cited by 3 publications

References 39 publications

A Rare Case of Prostate-Specific Antigen–Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance

A Rare Case of Prostate-Specific Antigen–Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance

Integrating a 92-Gene Expression Analysis for the Management of Neuroendocrine Tumors of Unknown Primary

Molecular Pathology of Lung Cancer

Contact Info

Product

Resources

About